http://www.healio.com/hematology-oncology/gynecologic-cancer/news/online/%7B6bf6df5e-0118-42b9-a163-25a7f6d31e4a%7D/dose-dense-carboplatinpaclitaxel-may-become-new-standard-for-ovarian-cancer
:
Katsumata N. Lancet Oncol. 2013;doi:10.1016/S1470-2045(13)70363-2.
A dose-dense carboplatin plus paclitaxel treatment regimen may offer a new standard of care for first-line chemotherapy in patients with advanced epithelial ovarian cancer, according to long-term follow-up data from the JGOG 3016 trial.
The investigators called for additional research to better identify the best dose, schedule and route of treatment administration.
The JGOG 3016 trial included 631 patients with stage II to IV ovarian cancer treated at 85 centers in Japan.
Researchers randomly assigned 319 patients to conventional treatment with carboplatin area under the curve (AUC) 6 mg/mL per minute and paclitaxel 180 mg/m2 on day 1). The other 312 patients received a dose-dense treatment with carboplatin AUC 6 mg/mL per minute on day 1 and paclitaxel 80 mg/m2 on days 1, 8 and 15.
Previously reported results from the primary analysis of the JGOG 3016 trial suggested the dose-dense regimen was associated with significant improvements in PFS and OS among women with epithelial ovarian, fallopian tube or primary peritoneal cancer.
For the long-term analysis, median follow-up was 76.8 months.
Data indicated that median PFS was significantly longer among patients assigned to the dose-dense regimen (28.2 months vs. 17.5 months; HR=0.76; 95% CI, 0.62-0.91). Women assigned to the dose-dense regimen also experienced significantly longer OS (100.5 months vs. 62.2 months; HR=0.79; 95% CI, 0.63-0.99).
“Several confirmatory trials using the dose-dense regimen with or without bevacizumab (Avastin, Genentech) are now ongoing in Europe and the United States,” the researchers wrote. “If these studies confirm the results of JGOG 3016, then it is likely that dose-dense chemotherapy will become an internationally accepted standard of care.”
Disclosure: This study was funded by the Japanese Gynecologic Oncology Group and Bristol-Myers Squibb. The researchers report honoraria and grant funding from Bristol-Myers Squibb and Nippon Kayaku.
